Dynavax Stock Today

Dynavax Technologies is trading at 18.79 as of the 28th of September 2021; that is 18.92 percent up since the beginning of the trading day. The stock's open price was 15.8. Equity ratings for Dynavax Technologies are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of July 2021 and ending today, the 28th of September 2021. Click here to learn more.
Valuation Options
Fiscal Quarter End 30th of September 2021

Dynavax Technologies Stock Profile

The next fiscal quarter end is expected on the 30th of September 2021. Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California. Dynavax Technologies operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 245 people. more on Dynavax Technologies
Dynavax Technologies is not yet fully synchronised with the market data
Dynavax Technologies has high likelihood to experience some financial distress in the next 2 years
Dynavax Technologies was previously known as Dynavax Technologies Corp and was traded on OTC Exchange under the symbol DVAXW.
The company reported the previous year's revenue of 169.07 M. Net Loss for the year was (5.7 M) with profit before overhead, payroll, taxes, and interest of 6.53 M.
Dynavax Technologies has a frail financial position based on the latest SEC disclosures
Over 76.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.fool.com: Why Dynavax Technologies Stock Is Soaring Today - The Motley Fool
Dynavax Technologies Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Dynavax Technologies SEC Filings
Dynavax Technologies SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameDynavax Technologies
Older SymbolDVAXW
CEO and DirectorEddie Gray  (View All)
Thematic Classification
Currently Active Investing Idea (view all)
  Pharmaceutical Products
Average Analyst Recommendation
Analysts covering Dynavax Technologies report their recommendations after researching Dynavax Technologies' financial statements, talking to executives and customers, or listening in on Dynavax Technologies' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Dynavax Technologies. The Dynavax consensus assessment is calculated by taking the average forecast from all of the analysts covering Dynavax Technologies.
Strong Buy3 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Dynavax Technologies based on its profitability, leverage, liquidity, source of funds, and operating efficiency. it is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Dynavax Technologies financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 2 - FrailDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares108.7 M100.8 M
Significantly Up
Increasing
Slightly volatile
Weighted Average Shares Diluted109.5 M101.5 M
Significantly Up
Increasing
Slightly volatile
Total Assets295.9 M353.3 M
Fairly Down
Increasing
Slightly volatile
Total Liabilities317.8 M294.6 M
Significantly Up
Increasing
Slightly volatile
Current Assets247.8 M290 M
Fairly Down
Increasing
Slightly volatile
Current Liabilities83.5 M77.4 M
Significantly Up
Increasing
Slightly volatile
Total Debt231.5 M214.6 M
Significantly Up
Increasing
Slightly volatile
Gross Margin0.760.701
Significantly Up
Decreasing
Slightly volatile
Asset Turnover0.120.144
Fairly Down
Decreasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Dynavax Technologies' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Not RatedOvervalued
Financial Strength
Dynavax Technologies' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Dynavax Technologies' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Dynavax Technologies' financial leverage. It provides some insight into what part of Dynavax Technologies' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Dynavax Technologies' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Dynavax Technologies deploys its capital and how much of that capital is borrowed.
Liquidity
Dynavax Technologies cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 256.34 M in liabilities with Debt to Equity (D/E) ratio of 3.07, implying the company greatly relies on financing operations through barrowing. Dynavax Technologies has a current ratio of 2.79, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Operating Cash Flow

(99.53 Million)Share
Dynavax Technologies (DVAX) is traded on NASDAQ Exchange in USA. It is located in 2100 Powell Street Suite 900, Emeryville, CA 94608, United States and employs 245 people. Dynavax Technologies was previously known as Dynavax Technologies Corp and was traded on OTC Exchange under the symbol DVAXW. Dynavax Technologies is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with current market capitalization of 2.15 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Dynavax Technologies's market, we take the total number of its shares issued and multiply it by Dynavax Technologies's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Dynavax Technologies conducts business under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 114.56 M outstanding shares of which 20.28 M shares are currently shorted by private and institutional investors with about 8.95 trading days to cover. Dynavax Technologies currently holds about 345.8 M in cash with 105.26 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.01.
Check Dynavax Technologies Probability Of Bankruptcy

Dynavax Stock Price Odds Analysis

What are Dynavax Technologies' target price odds to finish over the current price? Based on a normal probability distribution, the odds of Dynavax Technologies jumping above the current price in 90 days from now is roughly 2.72%. The Dynavax Technologies probability density function shows the probability of Dynavax Technologies stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Dynavax Technologies has a beta of -0.048 suggesting as returns on benchmark increase, returns on holding Dynavax Technologies are expected to decrease at a much lower rate. During the bear market, however, Dynavax Technologies is likely to outperform the market. Moreover, the company has an alpha of 1.2188, implying that it can generate a 1.22 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Odds Down 18.79HorizonTargetOdds Up 18.79 
97.26%90 days
 18.79 
2.72%
Based on a normal probability distribution, the odds of Dynavax Technologies to move above the current price in 90 days from now is roughly 2.72 (This Dynavax Technologies probability density function shows the probability of Dynavax Stock to fall within a particular range of prices over 90 days) .

Dynavax Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Dynavax Technologies that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Dynavax Technologies' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Dynavax Technologies' value.
InstituionSecurity TypeTotal SharesValue
Federated Hermes IncCommon Shares14.2 M140.3 M
Bain Capital Life Sciences Investors LlcCommon Shares11.8 M116 M
View Dynavax Technologies Diagnostics

Dynavax Technologies Historical Income Statement

Dynavax Technologies Income Statement is one of the three primary financial statements used for reporting Dynavax's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Dynavax Technologies revenue and expense. Dynavax Technologies Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Dynavax Technologies Cost of Revenue is fairly stable at the moment as compared to the past year. Dynavax Technologies reported Cost of Revenue of 13.91 Million in 2020. Gross Profit is likely to rise to about 35.2 M in 2021, whereas Consolidated Income is likely to drop (81.2 M) in 2021. View More Fundamentals

Dynavax Stock Against Markets

Picking the right benchmark for Dynavax Technologies stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Dynavax Technologies stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Dynavax Technologies is critical whether you are bullish or bearish towards Dynavax Technologies at a given time.

View Currently Related Equities

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Dynavax Technologies stock to make a market-neutral strategy. Peer analysis of Dynavax Technologies could also be used in its relative valuation, which is a method of valuing Dynavax Technologies by comparing valuation metrics with similar companies.

Dynavax Technologies Corporate Directors

Dynavax Technologies corporate directors refer to members of a Dynavax Technologies board of directors. The board of directors generally takes responsibility for the Dynavax Technologies' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Dynavax Technologies' board members must vote for the resolution. The Dynavax Technologies board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Stanley Plotkin - Independent DirectorProfile
Francis Cano - Independent DirectorProfile
Dan Kisner - Independent DirectorProfile
Daniel Kisner - Independent DirectorProfile
Continue to Investing Opportunities. Note that the Dynavax Technologies information on this page should be used as a complementary analysis to other Dynavax Technologies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Complementary Tools for Dynavax Stock analysis

When running Dynavax Technologies price analysis, check to measure Dynavax Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dynavax Technologies is operating at the current time. Most of Dynavax Technologies' value examination focuses on studying past and present price action to predict the probability of Dynavax Technologies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Dynavax Technologies' price. Additionally, you may evaluate how the addition of Dynavax Technologies to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Equity Search
Search for activelly traded equities including funds and ETFs from over 30 global markets
Go
The market value of Dynavax Technologies is measured differently than its book value, which is the value of Dynavax that is recorded on the company's balance sheet. Investors also form their own opinion of Dynavax Technologies' value that differs from its market value or its book value, called intrinsic value, which is Dynavax Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dynavax Technologies' market value can be influenced by many factors that don't directly affect Dynavax Technologies underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dynavax Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine Dynavax Technologies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dynavax Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.